A Phase I, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of DHES0815A in Patients With HER2-Positive Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs DHES-0815A (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Genentech; Roche
- 23 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 30 Jul 2018 Planned End Date changed from 13 Nov 2021 to 1 Jan 2022.
- 30 Jul 2018 Planned primary completion date changed from 13 Nov 2021 to 1 Jan 2022.